Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties
Lists
Only you see this
Abstract
We describe the synthesis of triazole-containing carboline derivatives and their utility as bromodomain and extra-terminal (BET) inhibitors. A convergent synthetic route permitted the detailed investigation of deuteration and fluorination strategies to reduce clearance while maintaining a favorable <i>in vitro</i> profile. This work led to the identification of a potent BET inhibitor, 2-{8-fluoro-3-[4-(<sup>2</sup>H<sub>3</sub>)methyl-1-methyl-1<i>H</i>-1,2,3-triazol-5-yl]-5-[(<i>S</i>)-(oxan-4-yl)(phenyl)methyl]-5<i>H</i>-pyrido[3,2-<i>b</i>]indol-7-yl}propan-2-ol (<b>15</b>), which demonstrated reduced clearance and an improved pharmacokinetic (PK) profile across preclinical species. Importantly, no major metabolite was observed when <b>15</b> was incubated with human hepatocytes (hHEP) for 2 h. This study culminated with the evaluation of <b>15</b> in a mouse triple-negative breast cancer (TNBC) tumor model where it demonstrated robust efficacy at low doses.
BibTeX
@inproceedings{hill2022development,
author = {Matthew D. Hill and Haiquan Fang and Derek Norris and George V. Delucca and Hong Huang and Mikkel DeBenedetto and Claude Quesnelle and William D. Schmitz and John S. Tokarski and S. Sheriff and Chunhong Yan and Caroline Fanslau and Zuzana Haarhoff and Christine Huang and Melissa Kramer and Shilpa Madari and Krista Menard and Laura Monereau and J. S. Morrison and Nirmala Raghavan and Eric Shields and Jean Simmermacher-Mayer and Michael Sinz and Ching Kim Tye and Richard A. Westhouse and Chunshan Xie and Haiying Zhang and Lisa Zhang and Tatyana Zvyaga and Francis Lee and Ashvinikumar V. Gavai and Andrew P. Degnan},
title = {{Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties}},
booktitle = {ACS},
year = {2022},
doi = {10.1021/acsmedchemlett.2c00219},
}Loading related content...